Stuttgart
20.12.24
09:43 Uhr
1,920 Euro
-0,018
-0,93 %
-0,93 %
1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 1,940 | 1,996 | 21.12. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Do | Crossject confirms ZEPIZURE supply chain readiness with another successful ISO audit for Quality Management System | 40 | GlobeNewswire (Europe) | Crossject successfully passes another ISO 13485 audit for sites in Dijon and Gray (France)Company is ramping up supply chain to prepare for commercialization in U.S. Dijon, France, December 19, 2024... ► Artikel lesen | |
| 11.12. | Crossject announces the pricing of its reserved capital increase and warrants issuance for an aggregate amount of EUR 7.2M | 2 | GlobeNewswire (USA) | ||
| 10.12. | Crossject launches reserved capital increase and warrants issuance for an aggregate amount of at least €7m | 1 | GlobeNewswire (USA) | ||
| 09.12. | Crossject and the U.S. Department of Defense Relaunch Joint Research on Needle-free Autoinjectors, Extending Their Cooperative Research and Development Agreement | 1 | GlobeNewswire (USA) | ||
| 13.11. | Crossject's ZENEO Auto-Injector's usability further demonstrated in extreme HAZMAT conditions | 1 | GlobeNewswire (USA) | ||
| 22.10. | Crossject reports strong manufacturing progress with its epilepsy rescue therapy ZEPIZURE ahead of filing U.S. Emergency Use Authorization | 86 | GlobeNewswire (Europe) | Product batch announced in July yielded new regulatory stability data. These results will directly support the requested 6-month stability data in the first quarter of 2025Crossject expects to file... ► Artikel lesen | |
| CROSSJECT Aktie jetzt für 0€ handeln | |||||
| 26.09. | Crossject announces its eligibility for France's PEA-PME investment scheme | 1 | GlobeNewswire (USA) | ||
| 23.09. | Crossject reports financial results and business highlights for the first six months of 2024 | 193 | GlobeNewswire (Europe) | Available cash €5.95 million, up from €2.3 million on December 31, 2023Reports stable investments in R&D and consolidation of operating income from BARDACompany on track to successfully file for the... ► Artikel lesen | |
| 17.09. | Crossject to report first-half 2024 financial results and host webcast on September 23, 2024 | 1 | GlobeNewswire (USA) | ||
| 22.08. | Crossject to Present at the H.C. Wainwright 26th Annual Global Investment Conference, September 9th-11th, 2024 | 1 | GlobeNewswire (USA) | ||
| 19.08. | Crossject appoints Tony Tipton as U.S. Chief Operating Officer in Preparation for Commercialization of ZEPIZURE Epilepsy Rescue Treatment | 183 | GlobeNewswire (Europe) | Press Release Crossject appoints Tony Tipton as U.S. Chief Operating Officer in Preparation for Commercialization of ZEPIZURE® Epilepsy Rescue Treatment Experienced executive to lead preparations... ► Artikel lesen | |
| 18.07. | Crossject achieves key ZEPIZURE manufacturing milestone | 133 | GlobeNewswire (Europe) | Successful completion of an additional Registration Batch of ZEPIZURE® at new manufacturing siteMilestone complements the satisfying results from previous batches under stability studies, and is... ► Artikel lesen | |
| 15.07. | Crossject to attend H.C. Wainwright 26th Annual Global Investment Conference | 2 | GlobeNewswire (USA) | ||
| 10.07. | Crossject is awarded a 6.9 million euros financing from the French Government, as part of the France 2030 innovation plan, to accelerate the development of ZENEO Epinephrine | 154 | GlobeNewswire (Europe) | Key contribution to the acceleration of the development of ZENEO® EpinephrineFinancial support includes mainly grants, as well as subsidized loansFrance 2030 Plan dedicated to supporting French companies... ► Artikel lesen | |
| 26.06. | Crossject elaborates on ZEPIZURE potential in light of landmark RAMPART study and its own, recently published, bioequivalence study | 187 | GlobeNewswire (Europe) | Landmark RAMPART study established midazolam intramuscular (IM) injection as a standard of care in the pre-hospital emergency management of epilepsy crises compared to traditional benzodiazepine... ► Artikel lesen | |
| 12.06. | Crossject appoints Dan Chiche, MD as Chief Medical Officer North America | 201 | GlobeNewswire (Europe) | Brings extensive experience in drug development in the U.S and internationally and in maximizing value of medical productsReinforces leadership team and expands presence in North AmericaSupports processes... ► Artikel lesen | |
| 14.05. | XFRA CAPITAL ADJUSTMENT INFORMATION - 14.05.2024 | 657 | Xetra Newsboard | Das Instrument 3W1 SE0000236382 CONCEJO AB (PUBL) B SK 5 EQUITY wird ex Kapitalmassnahme gehandelt am 14.05.2024 The instrument 3W1 SE0000236382 CONCEJO AB (PUBL) B SK 5 EQUITY is traded ex capital... ► Artikel lesen | |
| 25.04. | Crossject reports audited financial results for 2023 | 192 | GlobeNewswire (Europe) | Dijon, France April 25, 2024 -- Crossject (ISIN: FR0011716265; Euronext: ALCJ), a specialty pharmaceuticals company developing products for emergency situations harnessing its proprietary needle-free... ► Artikel lesen | |
| 08.04. | XFRA 74C: WIEDERAUFNAHME/RESUMPTION | 231 | Xetra Newsboard | FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME... ► Artikel lesen | |
| 02.04. | Crossject advances in its U.S. Strategy and reports Financial Results for 2023 | 277 | GlobeNewswire (Europe) | Increase in visibility in its regulatory and commercialization prospects in the U.S. since latest interactions with the FDAExpectation to receive U.S. Emergency Use Authorization (EUA) for ZEPIZURE®... ► Artikel lesen |
Seite:
1 2 Weiter >>
24 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| FRESENIUS | 33,200 | -0,84 % | Fresenius SE Aktie: Positiver Umsatztrend! | Die Fresenius SE-Aktie zeigt sich im aktuellen Handelsverlauf an der XETRA mit wechselhafter Tendenz. Nach einem Handelsstart bei 34,92 EUR bewegte sich der Kurs im Tagesverlauf zwischen verschiedenen... ► Artikel lesen | |
| INTUITIVE SURGICAL | 502,90 | -0,02 % | $100 Invested In Intuitive Surgical 5 Years Ago Would Be Worth This Much Today | ||
| SERNOVA | 0,146 | -3,95 % | Sernova Corp.: Sernova Reschedules its Annual General and Special Meeting of Shareholders to January 10, 2025 | ||
| VITA 34 | 4,120 | +2,49 % | Original-Research: Vita 34 AG (von Montega AG): Vita 34 AG | Original-Research: Vita 34 AG - von Montega AG 27.11.2024 / 10:10 CET/CEST Veröffentlichung einer Research, übermittelt durch EQS News - ein Service der EQS Group AG. Für den Inhalt der Mitteilung... ► Artikel lesen | |
| GERATHERM MEDICAL | 3,600 | +5,88 % | Geratherm Medical Aktie: Keine Überraschungen erwartet | Die Geratherm Medical AG verzeichnete in den vergangenen Tagen einen beachtlichen Kursanstieg von 28 Prozent. Der aktuelle Aktienkurs liegt bei 3,79 EUR (Stand: 14. Dezember 2024). Diese Entwicklung... ► Artikel lesen | |
| ALIGN TECHNOLOGY | 204,00 | +0,74 % | Align Technology-Aktie: Kurs klettert leicht (205,3929 €) | Im US-amerikanischen Wertpapierhandel notiert die Aktie von Align Technology gegenwärtig fester. Der jüngste Kurs betrug 213,13 US-Dollar. Ein Kursplus in Höhe von 49 Cent erfreut derzeit die Aktionäre... ► Artikel lesen | |
| NUGEN MEDICAL DEVICES | 0,052 | -1,14 % | NuGen Medical: Erster landesweiter Verkauf startet jetzt…. | ||
| PLUS THERAPEUTICS | 0,998 | -3,67 % | Plus Therapeutics Inc.: Plus Therapeutics Presents Positive ReSPECT-LM Phase 1 Interim Data for Breast Cancer Patients with Leptomeningeal Metastases at the 2024 San Antonio Breast Cancer Symposium | ||
| CARDINAL HEALTH | 113,70 | +0,26 % | Is Cardinal Health Stock Underperforming the Dow? | ||
| RESMED | 228,50 | +0,40 % | Eli Lilly's Obesity Drug Wins Approval In Sleep Apnea; Will ResMed Dive? | ||
| ATOSSA THERAPEUTICS | 0,934 | +0,65 % | Atossa Therapeutics, Inc.: Atossa Therapeutics Announces Full Results from Phase 2 KARISMA-Endoxifen Study Demonstrating Statistically Significant Reductions in Mammographic Breast Density | 1 MG Dose (Z)-Endoxifen Shows Potential as a Well-Tolerated, Preventative Therapy for Premenopausal Women at Risk of Developing Breast Cancer Data to be Presented in a Poster Spotlight Session During... ► Artikel lesen | |
| DAVITA | 146,65 | +0,69 % | DaVita Stock Sees Improved Relative Strength Rating | ||
| MEDICLIN | 2,460 | +1,65 % | EQS-PVR: MEDICLIN AG: Veröffentlichung gemäß § 40 Abs. 1 WpHG mit dem Ziel der europaweiten Verbreitung | EQS Stimmrechtsmitteilung: MEDICLIN AG
MEDICLIN AG: Veröffentlichung gemäß § 40 Abs. 1 WpHG mit dem Ziel der europaweiten Verbreitung
09.12.2024 / 11:30 CET/CEST
Veröffentlichung... ► Artikel lesen | |
| EVOFEM BIOSCIENCES | - | - | Evofem Biosciences, Inc.: Evofem Biosciences Announces Financial Results for the Third Quarter of 2024 | - Improved loss from operations by 31% -
- Acquired SOLOSEC, a commercially attractive, single-dose oral antibiotic FDA-approved to treat two pervasive sexual health... ► Artikel lesen | |
| UNIDOC HEALTH | 0,310 | 0,00 % | UniDoc Health Corp. blickt zurück auf ein Jahr des Wachstums und der Innovation | - Strategische Partnerschaften und KI-Integration positionieren UniDoc als E-Health-Lösung
VANCOUVER, British Columbia, 17. Dezember 2024 / IRW-Press / UniDoc Health Corp.... ► Artikel lesen |
Das Unternehmen CROSSJECT SA kann der Branche Gesundheitswesen zugeordnet werden. Der aktuelle Kurs liegt bei 1,920 Euro und damit -0,93 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu CROSSJECT SA finden Sie auf Wallstreet Online.
